NEW YORK (GenomeWeb News) – Beckman Coulter Life Sciences on Thursday announced the acquisition of the flow cytometry business assets of ReaMetrix India for an undisclosed amount.
Beckman Coulter LS said that the deal provides it with "temperature-stable, single-dose, multicolor antibody cocktails targeting the HIV monitoring and clinical research markets." It added that ReaMetrix's products complement its flow cytometry product portfolio with reagents that streamline the sample preparation process and provide standardized reagent combinations to cytometry labs.
ReaMetrix is based in Bangalore, India. Its dry temperature-stable flow cytometry reagents are CE marked for use in Europe, but are not available or cleared for use in the US.
"The simplification of customer workflows will be dramatic," Mario Koksch, VP and GM of the Cytometry Business Unit at Beckman Coulter LS, said in a statement. "We'll be able to offer customers an extended line of market-leading technology while expanding our reach within two key segments for flow cytometry — HIV monitoring and clinical research."
ReaMetrix CEO Bala Manian added that for his firm, "Beckman Coulter Life Sciences represents an opportunity to provide the global customer with an integrated and optimized solution involving both hardware and reagents. From our point of view, we now have the best chance of benefiting the intended target population as well as impacting the productivity of cytometrists around the world."